quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 16, 2026

Aduro Clean Technologies présente les résultats financiers de son deuxième trimestre 2026 et fait le point sur ses activités

View original at globenewswire.com
Aduro Clean Technologies présente les résultats financiers de son deuxième trimestre 2026 et fait le point sur ses activités LONDON, Province de l’Ontario, 16 janv…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Operating loss increased 107% to $(6,461,987) in Q2 FY2026 vs $(3,114,712) in Q2 FY2025, driven by share-based compensation, derivative financial liability revaluation loss, increased R&D, technology scaling, hiring, marketing/PR, and Nasdaq listing costs

    80% confidence
  • Adjusted EBITDA provides nuanced operational performance view and shows amounts available for working capital and future growth

    80% confidence
  • Revenue increased 222% in Q2 FY2026 to $122,706 CAD compared to $38,143 in Q2 FY2025

    80% confidence
  • Final site selection for Netherlands demonstration plant expected by end of January 2026

    80% confidence
  • Shell GameChanger collaboration validated key process design assumptions under continuous operation and supports Aduro's scaling journey from pilot to demonstration phase

    80% confidence
  • Hydrochemolytic™ technology is cost-effective and operates at relatively low temperatures for plastic waste chemical recycling, heavy crude oil/bitumen upgrading, and renewable fuels transformation

    80% confidence
  • Steam cracking test results showed stable furnace operation with ethylene/propylene yields comparable to traditional fossil fuel-based feedstocks, providing favorable data supporting further evaluation of HCT-derived liquids for steam cracking applications

    80% confidence

Data points we hold from this source

Aduro Clean Technologies Inc. · adjusted ebitda-3299026 CAD
Aduro Clean Technologies Inc. · property plant equipment7729984 CAD
Aduro Clean Technologies Inc. · share based compensation1860246 CAD
Aduro Clean Technologies Inc. · other income-131172 CAD
Aduro Clean Technologies Inc. · derivative liability fair value change1284420 CAD
Aduro Clean Technologies Inc. · depreciation amortization149467 CAD
Aduro Clean Technologies Inc. · revenue122706 CAD
Aduro Clean Technologies Inc. · operating loss-3114712 CAD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Aduro Clean Technologies présente les résultats financiers de son deuxième trimestre 2026 et fait le point sur ses activités — Source | Via News | pt.VIA.NEWS